(2S,4R)-1-(2-(1H-1,2,3-triazol-1-yl)acetyl)-4-(4-fluoro-2-methylbenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide | 1221877-37-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,4R)-1-(2-(1H-1,2,3-triazol-1-yl)acetyl)-4-(4-fluoro-2-methylbenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide
• 英文别名: (2S,4R)-4-[(4-fluoro-2-methylphenyl)methyl]-N-[4-(4-fluorophenoxy)phenyl]-1-[2-(triazol-1-yl)acetyl]pyrrolidine-2-carboxamide
• CAS: 1221877-37-7
• 化学式: C₂₉H₂₇F₂N₅O₃
• 分子量: 531.562
• InChiKey: FNVFLSAQIBGLRQ-HRFSGMKKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  89.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1H-1,2,3-三唑-1-乙酸盐酸盐 、 (2S,4R)-4-(4-fluoro-2-methylbenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide 以gave Compound 6, (2S,4R)-1-(2-(1H-1,2,3-triazol-1-yl)acetyl)-4-(4-fluoro-2-methylbenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide (142 mg, 46%)的产率得到
  参考文献：
  名称：

  Acetanilide sphingosine-1-phosphate receptor antagonists

  摘要：

  本披露涉及鞘氨醇-1-磷酸（S1P）受体拮抗剂，包括含有S1P受体拮抗剂的组合物以及使用S1P受体拮抗剂的方法和制备S1P受体拮抗剂的过程。特别是，本披露涉及鞘氨醇-1-磷酸1（S1P1）受体拮抗剂，包括含有S1P1受体拮抗剂的组合物以及使用S1P1受体拮抗剂的方法，例如用于癌症治疗，并制备S1P1受体拮抗剂的过程。

  公开号：

  US08791102B2

文献信息

• Sphingosine-1-Phosphate Receptor Antagonists
  申请人：Ibrahim Mohamed Abdulkader

  公开号：US20110288076A1

  公开（公告）日：2011-11-24

  This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particularly, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.

  本公开涉及鞘氨醇-1-磷酸（S1P）受体拮抗剂，包括含有S1P受体拮抗剂的组合物，以及使用和制备S1P受体拮抗剂的方法。特别地，本公开涉及鞘氨醇-1-磷酸1（S1P1）受体拮抗剂，包括含有S1P1受体拮抗剂的组合物，以及使用S1P1受体拮抗剂的方法，例如用于治疗癌症，以及制备S1P1受体拮抗剂的方法。
• Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents
  申请人：Shankar Geetha

  公开号：US20110301188A1

  公开（公告）日：2011-12-08

  This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
• US8791102B2
  申请人：——

  公开号：US8791102B2

  公开（公告）日：2014-07-29
• US8802692B2
  申请人：——

  公开号：US8802692B2

  公开（公告）日：2014-08-12